argenx (ARGX) Highlights 2024 Strategic Priorities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
argenx Highlights 2024 Strategic Priorities
January 8, 2024 1:00 AM ESTReported $1.2 billion in preliminary* full-year 2023 global net product sales
Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024
Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN
Data from six Phase 2 proof-of-concept trials expected by end of 2024
Nominated four new pipeline candidates with IND filings expected by end of 2025
January 8, 2024, 7:00 AM CET
... More